Drug Profile
Dactinomycin - Tiziana Life Sciences
Alternative Names: Act D - Actavia Life Sciences; Actinomycin D; Nanoparticle-Actinomycin D; NP-Act D; RASP-101Latest Information Update: 25 Jan 2024
Price :
$50
*
At a glance
- Originator Rasna Therapeutics
- Developer Actavia Life Sciences
- Class Amides; Antineoplastics; Cytostatic antibiotics; Oxazines; Small molecules
- Mechanism of Action Immunosuppressants; RNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Acute myeloid leukaemia
Most Recent Events
- 17 May 2021 Dactinomycin has been protected with multiple issued as well as pending patents for treatment of Acute myelppid leukaemia and Myelodysplastic syndrome worldwide before May 2021
- 22 Oct 2020 No development reported - Phase-II for Acute myeloid leukaemia (Recurrent, Second-line therapy or greater) in Italy (IV) (Tiziana Biosciences website, October 2020)
- 27 Apr 2020 Tiziana Life Sciences files for patent protection with nanoparticle-Actinomycin D